Francis D. Pagani
University of Michigan
410 Papers
2.2K Citations
Francis D. Pagani is an academic researcher from University of Michigan. The author has contributed to research in topics: Medicine & Ventricular assist device. The author has an hindex of 78, co-authored 342 publications. Previous affiliations of Francis D. Pagani include Campbell University & Baylor College of Medicine.
Chat about Author
Papers
Impact of Left Ventricular Assist Device on Diabetes Management: An Evaluation through Case Analysis and Clinical Impact
Angela Subauste,Nazanene H. Esfandiari,Yunyan Qu,Elif A. Oral,Keith D. Aaronson,Francis D. Pagani,Roma G. Gianchandani +6 more
TL;DR: Patients with diabetes undergoing LVAD implantation demonstrated a significant reduction in insulin requirements, which underscores the importance of HF in the progression of insulin resistance.
4
HVAD to HeartMate 3 left ventricular assist device exchange: Best practices recommendations.
Christopher T. Salerno,Christopher S. Hayward,Shelley Hall,Daniel J. Goldstein,Diyar Saeed,Jan D. Schmitto,David J. Kaczorowski,Ezequiel J. Molina,Daniel Zimpfer,Steven Tsui,Edward G. Soltesz,Duc Thinh Pham,Nahush A. Mokadam,Arman Kilic,Erin Davis,Erika D. Feller,Angela Lorts,Scott C. Silvestry,Mark S. Slaughter,Evgenij V. Potapov,Pavan Atluri,Jennifer A Cowger,Francis D. Pagani +22 more
TL;DR: The goal of this document is to review important differences in the design of the HVAD and HeartMate 3 that are relevant to the medical management of patients supported with these devices, and to assess the technical aspects of an HvAD-to-HeartMate 2 exchange.
4
•Journal Article
The impact of new technology on a clinical practice.
Seema S. Sonnad,David S. Bach,Steven F. Bolling,William F. Armstrong,Francis D. Pagani,Michael J. Shea,Hilary M. Monaghan,G. M. Deeb +7 more
TL;DR: The use of the Freestyle stentless conduit in a single practice over time shows a distinct learning curve as valves are placed in younger, sicker patients who require more complex surgery.
4
Outcomes after transfer to a tertiary center for postcardiotomy cardiopulmonary failure.
TL;DR: Patients with postcardiotomy cardiac failure transported to a tertiary care center for advanced cardiac support had a nearly 50% survival, with excellent long-term survival of those discharged alive.
4
Continuous-Flow Left Ventricular Assist Device Thrombosis: A Solvable Problem.
TL;DR: Despite the significant advances with CF technology, the cumulative adverse event burden contributed by stroke, bleeding, device-related infection, and pump thrombosis is high and remains an obstacle to greater adoption of this therapy.
4